# Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

> **NCT02811978** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 81 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02811978
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-27
- **Primary completion:** 2018-05-07
- **Final completion:** 2018-11-10
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811978, "Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02811978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*